Sanofi (SNY) Expected to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is expected to issue its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect the company to announce earnings of $0.83 per share and revenue of $11.1756 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The firm had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the prior year, the firm earned $2.25 EPS. The business’s revenue was down 7.5% on a year-over-year basis. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Trading Up 0.3%

Shares of NASDAQ:SNY opened at $47.33 on Tuesday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The stock has a market cap of $115.44 billion, a PE ratio of 11.08, a P/E/G ratio of 1.37 and a beta of 0.45. The business has a 50 day moving average of $48.38 and a 200-day moving average of $48.75. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

Analysts Set New Price Targets

Several analysts recently weighed in on SNY shares. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $62.67.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC purchased a new position in Sanofi in the third quarter valued at approximately $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the third quarter valued at $30,000. Sittner & Nelson LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at $47,000. WealthCollab LLC grew its stake in shares of Sanofi by 21.6% during the 3rd quarter. WealthCollab LLC now owns 1,538 shares of the company’s stock worth $73,000 after acquiring an additional 273 shares during the period. Finally, Brown Brothers Harriman & Co. increased its holdings in Sanofi by 618.7% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,271 shares of the company’s stock worth $107,000 after acquiring an additional 1,955 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.